Terns Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation and amortization expense
Net accretion on marketable securities
Change in fair value of convertible notes
Change in deferred taxes and uncertain tax positions
Amortization of operating lease assets

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Other assets
Accrued interest, net of interest received
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities
Deferred rent

Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Purchase of investments
Purchase of marketable securities
Proceeds from maturities of marketable securities
Net cash used in investing activities
Cash flows from financing activities:
Net proceeds from the issuance of common stock and pre-funded warrants
Net proceeds from the issuance of common stock
Payment of deferred offering costs
Net proceeds from issuance of Series C convertible preferred stock
Net proceeds from initial public offering
Proceeds from notes receivable
Payment of loans payable
Proceeds from the issuance of common stock under employee stock purchase plan
Proceeds from stock option exercises
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for amounts included in the measurement of lease liabilities
Cash paid for taxes
Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities
Deferred offering costs included in accounts payable and accrued expense
Conversion of preferred stock to common stock upon closing of the initial public offering
Purchases of property and equipment on trade vendor credit
LAV Option exercise
Conversion of 2020 convertible promissory notes to Series C convertible preferred stock
Conversion of Bridge Loan to Series C convertible preferred stock
Extinguishment of Series B convertible preferred stock

Comments